



# JPM 2025

## Prospectus Report



PRESENTED BY  
kbDNA Inc.



# TABLE OF CONTENTS

Key Insights	.....	3
Major Acquisitions	.....	4
2025 Emerging Tech	.....	7
Companies to Watch	.....	9
Strategic Opportunities	.....	11

# A DECADE OF JPM DEALS


**\$656 billion completed**

Look-back of notable transactions (2015-2024)


## Key Insights

### Top 5 Acquiring Companies


Company	Deals	Spent
AbbVie	3	\$94.2 Billion
Gilead Sciences	3	\$37.8 Billion
Johnson & Johnson	3	\$35.4 Billion
Pfizer	3	\$35.1 Billion
Novartis	3	\$18.8 Billion



Annual Acquisitions by Amount (USD) 2015 - 2024

 **Top Indication:**  
Oncology

 **Underdog Technology:**  
Biosimilars

 **Event Coffee Price:**  
\$15/cup

# All Notable Acquisitions

(2015 - 2024)

Year	Acquirer	Target	Amount
2015	Pfizer	Hospira	\$17 Billion
2015	AbbVie	Pharmacyclics	\$21 Billion
2016	AbbVie	Stemcentrx	\$10.2 Billion
2016	Shire	Baxalta	\$32 Billion
2016	Abbott	St. Jude Medical	\$25 Billion
2017	Johnson & Johnson	Actelion	\$30 Billion
2017	Gilead Sciences	Kite Pharma	\$11.9 Billion
2017	Thermo Fisher Scientific	Patheon	\$7.2 Billion
2017	Becton Dickinson	C.R. Bard	\$24 Billion
2018	Boston Scientific	BTG plc	\$4.2 Billion
2018	Takeda	Shire	\$62 Billion
2018	GlaxoSmithKline	Tesaro	\$5.1 Billion
2018	Roche	Flatiron Health	\$1.9 Billion
2018	Celgene	Juno Therapeutics	\$9 Billion
2018	Sanofi	Bioverativ	\$11.6 Billion
2018	Takeda	TiGenix	\$630 Million
2018	Novartis	AveXis	\$8.7 Billion
2019	Bristol-Myers Squibb	Celgene	\$74 Billion
2019	Sanofi	Synthorx	\$2.5 Billion
2019	Novartis	The Medicines Company	\$9.7 Billion
2019	AbbVie	Allergan	\$63 Billion
2019	Eli Lilly	Loxo Oncology	\$8 Billion
2019	Roche	Spark Therapeutics	\$4.3 Billion
2019	Danaher	GE Biopharma	\$21.4 Billion
2019	Johnson & Johnson	Auris Health	\$3.4 Billion
2019	Vertex Pharmaceuticals	Semma Therapeutics	\$950 Million
2019	Biogen	Nightstar Therapeutics	\$800 Million

# All Notable Acquisitions

Continued..

Year	Acquirer	Target	Amount
2019	Astellas Pharma	Audentes Therapeutics	\$3 Billion
2019	AstraZeneca	Daiichi Sankyo	\$6.9 Billion
2019	Merck	Peloton Therapeutics	\$1.05 Billion
2019	Pfizer	Array BioPharma	\$11.4 Billion
2019	Stryker	Wright Medical	\$4 Billion
2019	Boston Scientific	Vertiflex	\$465 Million
2020	Gilead Sciences	Forty Seven Inc.	\$4.9 Billion
2020	AstraZeneca	Alexion Pharmaceuticals	\$39 Billion
2020	Thermo Fisher Scientific	Qiagen	\$11.5 Billion
2020	Illumina	Grail	\$8 Billion
2020	Alexion Pharmaceuticals	Portola Pharmaceuticals	\$1.4 Billion
2020	Novo Nordisk	Corvidia Therapeutics	\$2.1 Billion
2020	Gilead Sciences	Immunomedics	\$21 Billion
2020	Sanofi	Principia Biopharma	\$3.7 Billion
2020	Bayer	Asklepios BioPharmaceutical	\$4 Billion
2021	Merck	Accelaron Pharma	\$11.5 Billion
2021	Pfizer	Arena Pharmaceuticals	\$6.7 Billion
2021	Amgen	Five Prime Therapeutics	\$1.9 Billion
2022	Intellia	Editas	Undisclosed
2023	Amgen	Horizon Therapeutics	\$27.8 Billion
2024	Johnson & Johnson	Ambrx	\$2 Billion
2024	Merck	Harpoon Therapeutics	\$680 Million
2024	GSK	Aiolos Bio	\$400 Million
2024	Novartis	Calypso Biotech	\$425 Million
2024	Bristol-Myers Squibb	MyoKardia	\$13.1 Billion

# 2025 EXPECTATIONS

Technologies of interest, companies to watch and more.



Look forward to more acquisitional closes and market moves involving emerging technologies and innovative companies in the upcoming conference.

---

# EMERGING TECHNOLOGIES

5 AREAS BEING DISCUSSED

---

## CRISPR and Gene Editing

The realm of gene editing continues to astound with its potential to revolutionize treatments for genetic disorders. Companies like Intellia Therapeutics and CRISPR Therapeutics have been at the forefront, making significant strides in developing therapies that promise to cure previously untreatable conditions. Their ongoing research and potential partnerships will be closely watched.

---

## mRNA Technology

Following the success of mRNA vaccines, companies like Moderna and BioNTech are expanding the scope of mRNA technology to address a wider array of diseases. Their research into mRNA-based treatments for cancer, rare diseases, and other conditions will be a focal point of interest.

---

## CAR-T Cell Therapy

Gilead Sciences, through its subsidiary Kite Pharma, has been a key player in the CAR-T cell therapy space. This innovative treatment harnesses the power of the patient's immune system to fight cancer. The conference will likely spotlight advancements in CAR-T technology, focusing on its efficacy and broadening applications beyond hematologic malignancies.



---

# EMERGING TECHNOLOGIES

5 AREAS BEING DISCUSSED

---

## AI and Machine Learning

AI and machine learning are transforming the drug discovery process. Companies like Insilico Medicine and BenevolentAI are leveraging these technologies to accelerate the identification of novel drug candidates, streamline clinical trials, and personalize patient care. Insights into their latest developments will be eagerly anticipated.

---

## Cell and Gene Therapies

The promise of cell and gene therapies to provide long-lasting, if not permanent, solutions to genetic diseases remains a hot topic. Companies such as Bluebird Bio and Spark Therapeutics are leading the charge with their innovative approaches. Updates on their clinical trials and regulatory progress are expected to generate significant buzz.





---

# COMPANIES TO WATCH

## *6 Companies to keep an eye on*

---

### **Pfizer**

Pfizer has consistently been a major player in the pharmaceutical industry, known for its strategic acquisitions and robust pipeline. With a focus on expanding its portfolio in oncology and immunology, the company's latest moves and future plans will be under close scrutiny.

---

### **Johnson & Johnson**

With its recent acquisition of Ambrx, Johnson & Johnson is set to enhance its portfolio in advanced prostate cancer treatments. The company's strategies for integrating this acquisition and future plans for expansion in oncology will be a highlight of the conference.

---

### **Merck**

Merck's acquisition of Acceleron Pharma and Harpoon Therapeutics has significantly bolstered its cardiovascular and oncology pipelines. The company's ongoing efforts to innovate within these domains and potential new partnerships will be key topics of interest.



---

# COMPANIES TO WATCH

## *6 Companies to keep an eye on*

---

### **GSK**

GSK's acquisition of Aiolos Bio has expanded its respiratory biologics portfolio. The company's focus on developing cutting-edge treatments for respiratory diseases and potential announcements of new collaborations will be eagerly anticipated.

---

### **Novartis**

Novartis, with its acquisition of Calypso Biotech, is addressing autoimmune indications. The company's strategic direction in autoimmune therapies and updates on its development pipeline will draw considerable attention.

---

### **Bristol Myers Squibb**

Bristol-Myers Squibb's acquisition of MyoKardia has fortified its cardiovascular franchise. Insights into how the company plans to integrate this acquisition and further enhance its cardiovascular treatments will be a topic of keen interest.



# POTENTIAL STRATEGIC MOVES & PARTNERSHIPS

The JPM Conference has historically been a platform for announcing significant strategic partnerships and M&A activities. This year, attendees can expect to see:

## **Collaborations in Gene Editing:**

- Companies are likely to announce partnerships aimed at advancing CRISPR and other gene-editing technologies.

## **Expansion of mRNA Therapeutics:**

- Continuing the momentum from mRNA vaccine success, companies may unveil new collaborations to broaden the application of mRNA technology.

## **AI-Driven Drug Discovery:**

- Partnerships between AI-driven biotech firms and traditional pharmaceutical companies to accelerate drug discovery and development.

## **Innovations in CAR-T Therapy:**

- Joint ventures to enhance the efficacy and expand the indications of CAR-T cell therapies.

## **Investments in Rare Diseases:**

- Increased focus on developing therapies for rare and orphan diseases, potentially through strategic acquisitions and collaborations.

# CONCLUSION

As we approach the JPM Conference, the excitement is palpable. The event promises to showcase transformative technologies and impactful strategic moves that will shape the future of the biotechnology and pharmaceutical industries. Companies like Pfizer, Johnson & Johnson, Merck, GSK, Novartis, and Bristol-Myers Squibb are expected to take center stage with their innovative approaches and strategic initiatives.

Stay tuned for detailed reports and analyses as we delve deeper into the groundbreaking advancements and strategic directions unveiled at the conference.

The future of biotech looks brighter than ever, and the JPM Conference remains the premier platform for driving these innovations forward.

## kbDNA and JPM

As a leading innovator in specialty reagents, kbDNA has the unique advantage of working closely with emerging biotech and pharma companies to help develop their R&D molecules for scale-up. We continue to play an increasingly supportive role in preparing our clients data and material strategy specifically for presentation at JPM. These behind the scenes experiences allow us to share novel insights and further extend our support to the industry audience.

kbDNA delivers reliable bioreagents and custom synthesis for efficient, consistent research. To learn more about kbDNA and our role in the landscape of emerging technologies - contact us today.

[kbdna.com](http://kbdna.com)

+1 (781) 206-2235

[info@kbDNA.com](mailto:info@kbDNA.com)

